Alzheimer’s diseasemeta-analysisGlucagon-like peptide-1 receptor agonist (GLP-1RA)has been found to have a complex and extensive connection with Alzheimer's disease (AD). The study is to further determine the therapeutic effect of GLP-1RA on AD by means of meta-analysis. Computer search Pub...
31.Marzioni M, Alpini G, Saccomanno S, Candelaresi C, Venter J, Rychlicki C, Fava G, Francis H, Trozzi L, Glaser S, Benedetti A. Glucagon-like peptide-1 and its receptor agonist exendin-4 modulate cholangiocyte adaptive response to cholestasis.Gastroenterology. 2007;133:244-255.[PubMed...
New-generation antidiabetic agents, particularly those targeting the glucagon-like peptide-1 (GLP-1) pathway, represent a significant advancement in the treatment of type 2 diabetes. GLP-1 is an incretin hormone that is secreted in response to food intake, and it exerts multiple actions conducive...
Use of glucagon-like peptide-1 receptor agonists (GLP-1 RAs) is associated with increased risks for gallbladder or biliary diseases, with a higher risk for GLP-1 RA use in weight loss, according to a review published online March 28 in JAMA Internal Medi
These data suggest a strong beneficial action of the glucagon-like peptide-1 receptor agonist Exendin-4 in improving neurological outcomes by attenuating inflammatory responses induced by traumatic brain injury, which is of therapeutic potential for TBI....
glucagon-like peptide-1 receptor agonists (GLP-1RAs) are a class of antidiabetic drugs noted not only for their potent glucose-lowering effects but also for their cardiovascular and renal protective benefits. Various GLP-1RAs have been demonstrated to have significant benefits in in vitro and in...
In the past 2 decades, eight glucagon-like peptide-1 receptor agonists (GLP-1RAs) have been approved for the management of type 2 diabetes, each with its peculiar molecular structure, pharmacokinetics, and metabolic effects. Along with their marked glucose-lowering actions, which occur both at ...
37.Botfield HF, Uldall MS, Westgate CSJ, Mitchell JL, Hagen SM, Gonzalez AM, Hodson DJ, Jensen RH, Sinclair AJ. A glucagon-like peptide-1 receptor agonist reduces intracranial pressure in a rat model of hydrocephalus.Sci Transl Med. 2017;9.[PubMed][DOI][Cited in This Article:1][Cited...
and semaglutide. Insulin production is stimulated after an oral glucose load by the incretin hormones glucagon-like peptide-1 and glucosedependent insulinotropic polypeptide (GIP), which are both inactivated by dipeptidyl peptidase-4 (DPP-4). Those with type 2 diabetes may have a slowdown or stoppa...
Semaglutide, a Glucagon-like peptide 1 (GLP-1) receptor agonist marketed under the brand name Ozempic, is originally prescribed for diabetes treatment and obesity management. However, healthy individuals without a medical cause use Ozempic without medical supervision to improve their physical appearance ...